17 January 2018 - - Paris, France-based biopharmaceutical group Ipsen (Euronext: IPN; ADR: IPSEY) has appointed Richard Paulson as executive vice-president and chief executive officer of Ipsen North America, responsible for all commercial operations throughout the region, effective February 5th, the company said.
Paulson will assume oversight of all areas supporting the North American business, and will be a member of the Ipsen executive leadership team. The role reports directly to David Meek, CEO of Ipsen.
Paulson joins Ipsen from Amgen where he most recently served as vice-president and general manager of the oncology business unit. During his 10-year career at Amgen, he held a number of positions in the company, including general manager, Central and Eastern Europe, and subsequently general manager Germany, before assuming leadership positions in Amgen's oncology business unit.
Prior to joining Amgen, he held international positions in general management, marketing, and market access with Pfizer. He also served in a number of sales and marketing roles with increasing seniority for GlaxoWellcome in Canada.
Paulson holds an MBA from the University of Toronto.
Ipsen group develops and commercializes medicines in the therapeutic areas of oncology, neurosciences, and rare diseases. It has a growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma, and pancreatic cancer.
The company also has a well-established consumer healthcare business, with total sales close to EUR 1.6 bn in 2016, selling more than 20 drugs in over 115 countries and with a direct commercial presence in more than 30 countries.
Ipsen's R and D is s located in Paris-Saclay, France; Oxford, UK; Cambridge, US. The group has about 5,100 employees worldwide.